Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:4851 |
Name | pilocytic astrocytoma |
Definition | A childhood low-grade glioma that is characterized by cells that look like fibers when viewed under a microscope and is located_in the brain. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation benign neoplasm cell type benign neoplasm low grade glioma childhood low-grade glioma pilocytic astrocytoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
BRAF V600E | Dabrafenib | pilocytic astrocytoma | predicted - sensitive | detail... |
BRAF V600D | Dabrafenib + Trametinib | pilocytic astrocytoma | predicted - sensitive | detail... |
BRAF fusion | N/A | pilocytic astrocytoma | not applicable | detail... |
BRAF V600E | Dabrafenib + Trametinib | pilocytic astrocytoma | sensitive | detail... |
BRAF V600E | Cobimetinib + Vemurafenib | pilocytic astrocytoma | sensitive | detail... |
BRAF V600E | Selumetinib | pilocytic astrocytoma | sensitive | detail... |
BRAF fusion | Selumetinib | pilocytic astrocytoma | sensitive | detail... |
BRAF V600E | Vemurafenib | pilocytic astrocytoma | predicted - sensitive | detail... |
FGFR1 N546K | Pemigatinib | pilocytic astrocytoma | predicted - sensitive | detail... |
BRAF A598_T599insV | Dabrafenib | pilocytic astrocytoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01089101 | Phase Ib/II | Selumetinib | Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma | Active, not recruiting | USA | 0 |
NCT01734512 | Phase II | Everolimus | PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children | Completed | USA | 0 |
NCT01837862 | Phase Ib/II | Carboplatin + Mebendazole + Temozolomide + Vincristine Sulfate Bevacizumab + Irinotecan + Mebendazole | A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas | Completed | USA | 0 |
NCT01999270 | Phase I | Bevacizumab + Irinotecan | Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors | Completed | USA | 0 |
NCT03975829 | FDA approved | Dabrafenib + Trametinib | Pediatric Long-Term Follow-up and Rollover Study | Active, not recruiting | USA | SWE | NLD | ITA | ISR | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 2 |
NCT04541082 | Phase I | ONC206 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | Recruiting | USA | 0 |
NCT04923126 | Phase Ib/II | PD-0325901 | SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma | Recruiting | USA | 0 |
NCT05267106 | Phase II | Pemigatinib | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DNK | DEU | 1 |
NCT05503797 | Phase II | Cobicistat + PLX8394 PLX8394 | A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | Recruiting | USA | SWE | ITA | GBR | FRA | ESP | DEU | CAN | 1 |